Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.

http://www.wikidata.org/entity/Q34441748

about

Clinical use and applications of histone deacetylase inhibitors in multiple myeloma Trials with 'epigenetic' drugs: an update New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Romidepsin in the treatment of cutaneous T-cell lymphoma.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Cell death signaling and anticancer therapy Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat Managing multiple myeloma in the elderly: are we making progress?Romidepsin: a novel histone deacetylase inhibitor for cancer.Monoclonal antibodies in the treatment of multiple myeloma.Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.Panobinostat for the treatment of multiple myeloma.HDAC inhibitor-based therapies: can we interpret the code?Toxicological and metabolic considerations for histone deacetylase inhibitors.MEK inhibitors as a chemotherapeutic intervention in multiple myeloma.Experimental approaches in the treatment of multiple myeloma.The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.Future agents and treatment directions in multiple myeloma.Current and potential epigenetic targets in multiple myeloma.Romidepsin for the treatment of non-Hodgkin's lymphoma.Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.Practical Approaches to the Management of Dual Refractory Multiple Myeloma.Drugging the pain epigenome.Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.Panobinostat for the treatment of acute myelogenous leukemia.In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).Romidepsin for cutaneous T-cell lymphoma.Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.Emerging drugs and combinations to treat multiple myeloma.

P2860

Q26745930-5B42C2BE-DF1A-4A15-8291-9DDDE01CE55A Q27000542-E0058020-08B5-4586-BB97-54F9CACB724F Q27004421-1559179F-9257-46B4-B58E-404766B41AC1 Q34224278-D5F6A810-5BEF-448B-9AD9-86BCC3FA39DA Q34263870-69ACCB26-23F2-41D9-85DA-CCB6B51DEE07 Q34602263-ABBD9835-1E37-406D-BF98-A886CCDD0328 Q35683831-885485ED-BA7A-40E4-B77E-20AFF5E98872 Q35939690-84976AA7-EF6C-4AB9-8015-3E609E5DE033 Q35972102-12C22687-DDA3-4A73-8CF1-BD3BA739EB58 Q37083880-51F4BF1C-2A33-4984-A6BC-CBB8DC516308 Q37132187-956708F7-B7D1-42BC-8E64-7D6F5CA1824F Q37199772-0C248B2D-EE7E-4E82-8405-598A6A1A5C7A Q37888716-8AACB74F-0C53-45D2-8D5A-70C9B374FA42 Q37893664-59BD0E02-E134-4413-9039-91A0E5014B5A Q37903377-1DADC793-9948-4F90-800D-DF214093F414 Q37954600-541881A5-36B1-4AE0-B6D5-D6DD5B1702ED Q37992104-EA2AAC34-DD32-4A0D-ABEF-957428269A85 Q38058971-E999076D-FA57-41D3-A24F-762D3D001D9C Q38071321-2F5A6BB8-DD0D-4BB4-9778-A78BE4CC2764 Q38092584-84A41594-9E0B-42D8-BE03-A6EEA0E9DC54 Q38095958-2C9FE9CA-AAC5-4B68-9FA2-61E5A4037EAA Q38101381-D276064C-D017-4353-BCEB-6BB6A4F382DC Q38161731-C02F72D8-69A1-47C8-9A79-C3E5A4AD9440 Q38172300-220D5EB2-C707-4A1D-8082-57E7BE04FD84 Q38210475-82329C44-0D9F-4E5A-B71B-FC69A7A7E8BF Q38455740-5CC46F96-9E96-49CA-B366-2041438A1756 Q38616807-5CEEDEDA-9A80-4B8F-B96A-8DB34EF7BC73 Q38716460-D1855222-A835-4461-BB0B-4FD108B0EC5A Q38742700-832BCC13-3877-4F42-8AAB-81BF0905213D Q38761806-771033AC-B667-41FF-B04D-10FD4F98A3DD Q38813504-8E3450AD-CFB6-4BBC-83D6-E438F145DD0C Q38835113-9802C532-8565-44F3-B97A-78A64319278A Q38910971-8874E4F4-30B5-48F1-A788-C395478C9D66 Q38950582-ED4FF6A4-B65F-4FAA-8749-61499CC18188 Q39113061-A60EAD71-7361-4EEF-B46E-76A50D2C871D Q39185574-5AC00087-5ED0-42CB-980F-749873927C76 Q39248784-B643BC15-52D6-473D-A084-84B17848021D Q39303355-539B4074-3A7F-48F3-949F-8A26F66CC5CF Q39454860-D62A8010-C293-4E08-B399-8057F0324346 Q41694198-E471962B-0369-40BE-BB93-81AC02362E45

P2860

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.

http://www.wikidata.org/entity/Q34441748

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@ast

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@en

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@nl

type

label

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@ast

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@en

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@nl

prefLabel

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@ast

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@en

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@nl

P1433

Q34441748-C43C78BE-4C61-4E4C-8967-E7126E9782C9

P1476

Q34441748-8463B46B-DC55-43A8-93AA-C4144D8F16BF

P2093

Q34441748-2A83BB89-286D-46D4-A590-B1414AF22A82

Q34441748-376D5715-FB0E-44EA-A92E-1D3E9B18AB6F

Q34441748-3B155D7A-25C9-4F46-82CE-E3FEFB221C96

Q34441748-4E2FEAC4-BF19-4B35-A06E-51F15E4B28EA

Q34441748-7BFC6D21-33F4-4363-9CB7-01C6DDD68F7D

Q34441748-7D8635CA-6A27-4F8F-AF3F-95B8204A5925

Q34441748-AEBFC4E7-6684-4262-95A4-3606B6D218F0

P2860

Q34441748-0206AE9C-C44D-4DE9-A67E-44B296B34BED

Q34441748-050BBD1F-22CC-46A8-8B61-0CCED3041196

Q34441748-15BEA4F1-2290-41C2-A0E5-A9C88696AA5C

Q34441748-1604EEF5-DAF7-4CCD-897E-00E5089E0622

Q34441748-3A3F17A9-6F2E-44F9-923A-F5428FA108DA

Q34441748-4F267DF6-BA28-450F-8EA0-B9D874E1F895

Q34441748-572F399F-0408-4CD1-8911-6BF53D5127F9

Q34441748-5802283E-B474-41DE-9E33-E650906108A8

Q34441748-5E60118D-3B60-43AF-AB27-F75A270FAF65

Q34441748-70D4A210-2507-4B7D-9218-5E0A6466DD2D

P304

Q34441748-65407711-D5B0-48B3-8E81-B1156D4B0E09

P31

Q34441748-FB697F76-1AAB-40D5-92A4-BDAE429859E5

P356

Q34441748-34E94E40-D90D-4B8C-A186-93B998687E65

P407

Q34441748-2F216156-8FFB-4D4B-8134-A6E7256CB082

P433

Q34441748-49A0AC81-80FE-472A-A19F-F7BF10446A7D

P478

Q34441748-21F492C1-AFFC-4F05-930B-5715DE334940

P50

Q34441748-0CD08619-D6E7-4659-AD01-96DEC42E3967

P577

Q34441748-2E803AE6-62B7-4069-833C-E1882D12D6E8

P5875

Q34441748-F671ECAE-388A-4FE6-852C-4CD0B57FDBAF

P698

Q34441748-4EDE880B-B6CF-4BBD-BED8-B17B8CBB4C86

P921

Q34441748-003F68B5-41D1-485E-ACE4-0DE94D1E8299

P932

Q34441748-C6F3ABEE-DEB4-4141-B892-B8938AAE9372

P356

P1433

P1476

Phase 2 trial of the histone d ...... f refractory multiple myeloma.

@en

P2093

Janice L Gabrilove

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

Joseph A Sparano

http://www.w3.org/2001/XMLSchema#string

Sangeeta Aggarwal

http://www.w3.org/2001/XMLSchema#string

Scott Ely

http://www.w3.org/2001/XMLSchema#string

Selina Chen-Kiang

http://www.w3.org/2001/XMLSchema#string

Tomer Mark

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple myeloma

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

International uniform response criteria for multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma

P304

336-342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25584

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Ruben Niesvizky

P577

2010-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46404770

http://www.w3.org/2001/XMLSchema#string

P698

20862746

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3010462

http://www.w3.org/2001/XMLSchema#string